

- Ackerman NB.** The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. *Surgery*. 1974 Apr;75(4):589-96
- Agard C, Ligeza C, Dupas B, Izembart A, El Kouri C, Moullier P, Ferry N.** Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. *Cancer Gene Ther*. 2001 Feb;8(2):128-36
- Agbaria R, Candotti F, Kelley JA, Hao Z, Johns DG, Cooney DA, Blaese RM, Ford H Jr.** Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. *Biochem Biophys Res Commun*. 2001 Nov 30;289(2):525-30
- Aigner KR, Walther H, Tonn JC, Link KH, Schoch P, Schwemmle K.** Isolated liver perfusion in advanced metastases of colorectal cancers] *Onkologie*. 1984 Feb;7(1):13-21. German
- Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A.** Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives *in-vivo*. *Biochim Biophys Acta*. 1991 Jul 1;1066(1):29-36
- Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J.** Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. *Lancet*. 1994 Nov 5;344(8932):1255-60
- Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP, Curiel DT.** Adenoviral-mediated suicide gene therapy for ovarian cancer. *Mol Ther*. 2000 Nov;2(5):524-30
- Arndt D, Fichtner I, Liposomen, Fortschritte der Onkologie Band 13, Akademie-Verlag Berlin, S.7, 1986**
- AWMF Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Kurzgefasste Interdisziplinäre Leitlinien 2000, B10, Seite 182 ff oder [www.uni-duesseldorf.de/WWW/AWMF/ll/cho-lebm.htm](http://www.uni-duesseldorf.de/WWW/AWMF/ll/cho-lebm.htm), AWMF-Leitlinien-Register Nr. 032/019, 1999**
- Baer HU, Kulli C, Jensen EX,** Moderne chirurgische Behandlung von Lebermetastasen, Schweizerische Ärztezeitung, 2000; 81(44):2478-2481
- Bangham AD, Standish MM, Watkins JC.** Diffusion of univalent ions across the lamellae of swollen phospholipids. *J Mol Biol*. 1965 Aug;13(1):238-52
- Barba D, Hardin J, Ray J, Gage FH.** Thymidine kinase-mediated killing of rat brain tumors. *J Neurosurg*. 1993 Nov;79(5):729-35

- Baum C, Ostertag W**, Somatischer Gentransfer in der Oncologie, Onkologie 1, IV-21, Hrsg Zeller, zur Hausen, ecomed-Verlag, 2. Erg.Lfg 12/1996, S. 1-24
- Betageri GV, Jenkins SA, Parsons DL**, Liposome drug delivery systems, Technomic Publishing Co. Inc., Lancaster, Basel, 1993
- Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, et al.** T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. *Science*. 1995 Oct 20;270(5235):475-80
- Block A, Windler E, Greten H, Woo SL**. [Adenovirus gene therapy for liver metastases of gastrointestinal tumors. Development status and future prospectives] *Dtsch Med Wochenschr*. 1997 May 30;122(22):728-32. Review. German
- Boese-Landgraf J**, Epidemiologie, Vorstufen und und Pathogenese des kolorektalen Karzinoms, *Der Onkologe* 4 S1, 1998
- Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H**. Answering patients' needs: oral alternatives to intravenous therapy. *Oncologist*. 2001;6 Suppl 4:12-6. Review.
- Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B**. Prevalence of ras gene mutations in human colorectal cancers. *Nature*. 1987 May 28-Jun 3;327(6120):293-7
- Boucher PD, Ruch RJ, Shewach DS**. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. *Hum Gene Ther*. 1998 Apr 10;9(6):801-14
- Brach MA, Herrmann F**. [Principles and strategies of gene therapy] *Internist (Berl)*. 1996 Apr;37(4):343-9. Review. German
- Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M, Dorken B**. Liver-associated toxicity of the HSV-tk / GCV approach and adenoviral vectors. *Cancer Gene Ther*. 1997 Jan-Feb;4(1):9-16
- Brand K, Loser P, Arnold W, Bartels T, Strauss M**. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk / GCV approach. *Gene Ther*. 1998 Oct;5(10):1363-71
- Breedis C**, The blood supply of neoplasms of the liver, *American Journal of Pathology*, 1954, 30, 969-985
- Brust P, Haubner R, Friedrich A, Scheunemann M, Anton M, Koufaki ON, Hauses M, Noll S, Noll B, Haberkorn U, Schackert G, Schackert HK, Avril N, Johannsen B**. Comparison of [18F]FHPG and [124 / 125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. *Eur J Nucl Med*. 2001 Jun;28(6):721-9
- Burnette TC, de Miranda P**. Metabolic disposition of the acyclovir prodrug valaciclovir

in the rat. Drug Metab Dispos. 1994 Jan-Feb;22(1):60-4

**Burnette TC**, Harrington JA, Reardon JE, Merrill BM, de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem. 1995 Jun 30;270(26):15827-31

**Caruso M**. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Med Today. 1996 May;2(5):212-7. Review

**Caruso M**, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11302-6

**Chen SH**, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SL. Combination gene therapy for liver metastasis of colon carcinoma *in-vivo*. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2577-81

**Cheon J**, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C, Chung LW. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 1997 Nov-Dec;4(6):359-65

**Chung LW**, Kao C, Sikes RA, Zhau HE. Human prostate cancer progression models and therapeutic intervention. Hinyokika Kiyo. 1997 Nov;43(11):815-20. Review. Only Abstract.

**Coffey MC**, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998 Nov 13;282(5392):1332-4

**Connors TA**. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 1995 Dec;2(10):702-9. Review

**Crystal RG**, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J, Harvey BG. Phase I study of direct administration of a replication deficient adenovirus vector containing the *E. coli* cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997 May 20;8(8):985-1001

**Culver KW**, Blaese RM. Gene therapy for cancer. Trends Genet. 1994 May;10(5):174-8. Review

**Curley SA**, Hohn DC, Roh MS. Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. Langenbecks Arch Chir. 1990;375(2):119-24

**Dave J**, Patel HM. Differentiation in hepatic and splenic phagocytic activity during

reticuloendothelial blockade with cholesterol-free and cholesterol-rich liposomes. Biochim Biophys Acta. 1986 Sep 19;888(2):184-90

**de Roos WK**, Fallaux FJ, Marinelli AW, Lazaris-Karatzas A, von Geusau AB, van der Eb MM, Cramer SJ, Terpstra OT, Hoeben RC. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther. 1997 Jan;4(1):55-62

**Di Meco F**, Benedetti S, Colombo MP, Finocchiaro G. Perspectives for the gene therapy of malignant gliomas by suicide gene transfer. J Neurosurg Sci. 1997 Sep;41(3):227-34

**Eble MJ**, Gademann G, Wannenmacher M. [The value of radiotherapy for liver metastases] Strahlenther Onkol. 1993 Aug;169(8):459-68. German

**Elion GB**. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol. 1993;Suppl 1:2-6. Review

**Elion GB**, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, -5720 (1977)

**Estin D**, Li M, Spray D, Wu JK. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery. 1999 Feb;44(2):361-8; discussion 368-9

**Fachinfo Valtrex®**, Fa. GlaxoWellcome, April 2000

**Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759-67. Review

**Fong Y**. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999 Jul-Aug;49(4):231-55. Review

**Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21

**Forrester K**, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987 May 28-Jun 3;327(6120):298-303

**Freeman SM**, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN, The „Bystander effect“: Tumor regression when a fraction of the tumor mass is genetically modified, Cancer Research, 1993, 53, Nov 1, 5274-5283

**Freund CT**, Sutton MA, Dang T, Contant CF, Rowley D, Lerner SP. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer.

Anticancer Res. 2000 May-Jun;20(3A):1359-65

**Freund CT, Tong XW, Block A, Contant CF, Kieback DG, Rowley DR, Lerner SP.**

Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. Anticancer Res. 2000 Sep-Oct;20(5A):2811-6.

**Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, Speizer FE, Willett WC.** Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999 Jan 21;340(3):169-76

**Galanis E, Vile R, Russell SJ.** Delivery systems intended for *in-vivo* gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92. Review

**Gerolami R, Cardoso J, Lewin M, Bralet MP, Sa Cunha A, Clement O, Brechot C, Tran PL.** Evaluation of HSV-*tk* gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res. 2000 Feb 15;60(4):993-1001

**Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC.** Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst. 1995 Feb 15;87(4):265-73

**Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Kearney J, Willett WC.** A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst. 1994 Feb 2;86(3):183-91

**Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, Speizer FE.** A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994 Feb 2;86(3):192-9

**Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF.** Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000 Mar 15;92(6):486-92

**Guski H., Histopathologie, Herausgeber Kunz J., Verlag Volk und Wissen, 1980**

**Habib NA, Ding SF, el-Masry R, Mitry RR, Honda K, Michail NE, Dalla Serra G, Izzi G, Greco L, Bassyouni M, el-Toukhy M, Abdel-Gaffar Y.** Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev. 1996;20(2):103-7

**Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, Vernon CC, Gueret-**

Wardle D, El-Masry R, Salama H, Ahmed R, Michail N, Edward E, Jensen SL. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. *Hum Gene Ther.* 2001 Feb 10;12(3):219-26

**Haller** DG, Catalano PJ, McDonald JS, Fluorouracil (FU), Leucovorin (LV) and Levamisol (LEV) adjuvant therapy for colon cancer: five year final report of INT-0089 (ABS), Proceedings of the American Society of clinical oncology, 1998, 17: 3553-3559

**Hasegawa** Y, Nishiyama Y, Imaizumi K, Ono N, Kinoshita T, Hatano S, Saito H, Shimokata K. Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy. *Cancer Gene Ther.* 2000 Apr;7(4):557-62

**Hasenburg** A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. *Anticancer Res.* 1999 May-Jun;19(3B):2163-5

**Hasenburg** A, Tong XW, Fischer DC, Rojas-Martinez A, Nyberg-Hoffman C, Kaplan AL, Kaufman RH, Ramzy I, Aguilar-Cordova E, Kieback DG. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. *Gynecol Oncol.* 2001 Dec;83(3):549-54

**Hashizume** H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. *Am J Pathol.* 2000 Apr;156(4):1363-80

**Heim** ME, Gastrointestinale Tumoren, Onkologie 2, V-2.5, Hrsg Zeller, zur Hausen, ecomed-Verlag, 10. Erg.Lfg 11 / 2000, S. 10ff

**Herman** JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. *Hum Gene Ther.* 1999 May 1;10(7):1239-49

**Hnatowich** DJ, Friedman B, Clancy B, Novak M. Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. *J Nucl Med.* 1981 Sep;22(9):810-4

**Hollon** T, Gene therapy- a loss of innocence, *Nature medicine*, 2000;6 (1):1-2

**Hospers** GA, Calogero A, van Waarde A, Doze P, Vaalburg W, Mulder NH, de Vries EF. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography. *Cancer Res.* 2000 Mar 15;60(6):1488-91

**Hottenrott** C, Lorenz, Rossion C, Locoregionäre Chemotherapie im Gastrointestinalbereich, Onkologie 2, VI-2, Hrsg Zeller, zur Hausen, ecomed-Verlag, 2.Erg.Lfg 12/1996

**Jacobs** A, Voges J, Reszka R, Lercher M, Goßmann A, Kracht L, Kaestle C, Wagner R,

Wienhard K, Heiss WD. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. *Lancet*. 2001 Sep 1;358(9283):727-9

**Kamps JA, Koning GA, Velinova MJ, Morselt HW, Wilkens M, Gorter A, Donga J, Scherphof GL.** Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. *J Drug Target*. 2000;8(4):235-45

**Kemeny MM, Battifora H, Blayney DW, Cecchi G, Goldberg DA, Leong LA, Margolin KA, Terz JJ.** Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. *Ann Surg*. 1985 Aug;202(2):176-81

**Kessler H, Hermanek P Jr, Wiebelt H.** Operative mortality in carcinoma of the rectum. Results of the German Multicentre Study. *Int J Colorectal Dis*. 1993 Sep;8(3):158-66

**Klatzmann D, Cherin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, Boccaccio C, Salzmann JL, Herson S.** A phase I / II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. *Hum Gene Ther*. 1998 Nov 20;9(17):2585-94

**Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J.** A phase I / II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. *Hum Gene Ther*. 1998 Nov 20;9(17):2595-604.

**Kong G, Braun RD, Dewhirst MW.** Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. *Cancer Res*. 2000 Aug 15;60(16):4440-5

**Koning GA, Morselt HW, Gorter A, Allen TM, Zalipsky S, Kamps JA, Scherphof GL.** Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. *Pharm Res*. 2001 Sep;18(9):1291-8

**Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T.** Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. *Hepatology*. 1995 Dec;22(6):1838-46

**Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K, Tsujii T.** Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. *Anticancer Res*. 1996 Sep-Oct;16(5A):2623-8

**Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Akahane T, Mitoro A, Tominaga**

K, Tsujinoue H, Yoshiji H, Okamoto S, Fukui H, Ikenaka K. Cancer gene therapy with HSV-tk / GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells *in-vivo*. *Int J Cancer.* 1999 Oct 29;83(3):374-80.

**Kianmanesh AR**, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, Klatzmann D. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. *Hum Gene Ther.* 1997 Oct 10;8(15):1807-14

**Kim SH**, Kim JH, Kolozsvary A, Brown SL, Freytag SO. Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. *J Neurooncol.* 1997 Jul;33(3):189-94

**Kirn D**. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? *Gene Ther.* 2001 Jan;8(2):89-98. Review.

**Kwong YL**, Chen SH, Kosai K, Finegold M, Woo SL. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer. *Chest.* 1997 Nov 5;112(5):1332-7

**Lasic DD**, Liposomes: From Physics to Applikation, Elsvier, 1993, 366/390,

**LeMay DR**, Kittaka M, Gordon EM, Gray B, Stins MF, McComb JG, Jovanovic S, Tabrizi P, Weiss MH, Bartus R, Anderson WF, BV. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. *Hum Gene Ther.* 1998 May 1;9(7):989-95

**Link CJ Jr**, Levy JP, McCann LZ, Moorman DW. Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. *J Surg Oncol.* 1997 Apr;64(4):289-94

**Litzinger DC**, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. *Biochim Biophys Acta.* 1994 Feb 23;1190(1):99-107

**Loser P**, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. *J Virol.* 1998 Jan;72(1):180-90

**Mader RM**, Muller M, Steger GG. Resistance to 5-fluorouracil. *Gen Pharmacol.* 1998 Nov;31(5):661-6. Review

**Markert JM**, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. *Gene Ther.* 2000 May;7(10):867-74.

**Martuza RL**. Conditionally replicating herpes vectors for cancer therapy. *J Clin Invest.*

2000 Apr;105(7):841-6. Review

- Marquet RL, Westbroek DL, Jeekel J.** Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. *Int J Cancer.* 1984 May 15;33(5):689-92
- Mendenhall WM, Bland KI, Copeland EM 3rd, Summers GE, Pfaff WW, Souba WW, Million RR.** Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? *Ann Surg.* 1992 Jun;215(6):696-705; discussion 705-6.
- Meyer HJ, Lux,G Hohenberger W, Klar E, Lange J, Kolorektales Karzinom, Interdiziplinäres Gespräch, Chirurgische Gastroenterologie,** 2000; 16: 280-282
- McMasters RA, Saylor RL, Jones KE, Hendrix ME, Moyer MP, Drake RR.** Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. *Hum Gene Ther.* 1998 Oct 10;9(15):2253-61
- McGuill MW, Rowan AN,** Biological effects of blood loss: Implications for sampling volumes and techniques, *Ilar News,* 1998, 31(4): 5-20
- Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J, Galle PR, Cornelis JJ.** Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. *Cancer Gene Ther.* 2001 Mar;8(3):158-67
- Moghimi SM, Patel HM.** Differential properties of organ-specific serum opsonins for liver and spleen macrophages. *Biochim Biophys Acta.* 1989 Sep 18;984(3):379-83
- Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN.** The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. *Cancer Res.* 1993 Nov 1;53(21):5274-83
- Müller P, Schlimok G.** [Development and use of anti-epithelial antibodies in solid tumors] *Internist (Berl).* 2001 Jun;42(6):827-34. Review. German.
- Needham D, McIntosh TJ, Lasic DD.** Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. *Biochim Biophys Acta.* 1992 Jul 8;1108(1):40-8
- Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D.** Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. *Gene Ther.* 2001 May;8(10):746-59
- Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya**

J, Baba S, Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science*. 1991 Aug 9;253(5020):665-9

**Norman KL, Farassati F, Lee PW.** Oncolytic viruses and cancer therapy.

*Cytokine Growth Factor Rev.* 2001 Jun-Sep;12(2-3):271-82. Review

**Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ.** Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. *Cancer Gene Ther.* 2001 Dec;8(12):958-65

**Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW.** Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. *Cancer Res.* 1993 Aug 15;53(16):3765-70

**O'Malley BW** in *Gene Therapy*, eds. Templeton N, Lasic DD, New York Dekker 2000, Cap. 17 Suicide Gene Therapy, 353 ff

**Ormrod D, Goa K.** Valaciclovir: a review of its use in the management of herpes zoster. *Drugs*. 2000 Jun;59(6):1317-40. Review

**Ott R, Wein A, Hohenberger W.** [Liver metastases--primary or multimodal therapy?] *Chirurg*. 2001 Aug;72(8):887-97. Review. German

**Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, et al.** Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. *Proc Natl Acad Sci U S A*. 1991 Dec 15;88(24):11460-4

**Passarge E.** Tumorerkrankungen- Einführung aus genetischer Sicht, Molekularmedizinische Grundlagen von hereditären Tumorerkrankungen, Springer, 2001, Hrsg. Ganten D, Ruckpaul, 3-12

**Pohlen U, Berger G, Binnenhei M, Reszka R, Buhr HJ.** Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): an experimental study in liver tumor-bearing rabbits. *J Surg Res.* 2000 Aug;92(2):165-70

**Produkt-Monographie Spherex® DSM 45 / 25**, Pharmacia & Upjohn, September 1997

**Qian C, Idoate M, Bilbao R, Sangro B, Bruna O, Vazquez J, Prieto J.** Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. *Hum Gene Ther.* 1997 Feb 10;8(3):349-58

**Rainov NG, Kramm CM, Banning U, Riemann D, Holzhausen HJ, Heidecke V, Burger KJ, Burkert W, Korholz D.** Immune response induced by retrovirus-mediated HSV-tk / GCV pharmacogene therapy in patients with glioblastoma multiforme. *Gene Ther.* 2000 Nov;7(21):1853-8

- Ragnhammar** P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. *Acta Oncol.* 2001;40(2-3):282-308. Review
- Reszka** RC, Pohlen U, Schlüter R, Berndt A, Berger I, Lehmann C, Binnenhei M, Winter R, Berger G, A new application system for drug targeting into the anigenetic area of the liver, 2002, zur Veröffentlichung eingereicht
- Ruf** G et al, "Empfehlungen zu standardisierten Diagnostik, Therapie und Nachsorge Kolorektales Karzinom", Feb., 2000, [www.tumorzentrum-freiburg.de](http://www.tumorzentrum-freiburg.de)
- Riethmuller** G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. *J Clin Oncol.* 1998 May;16(5):1788-94
- Roche** media roundtable, „Neue Strategien zur Krebsbekämpfung“ Prenzberg, September 2001, Hrsg. F. Hoffmann- La Roche AG, Corporate Communications, 4070 Basel, Schweiz, Editions Roche 2001
- Rodriguez-Bigas** MA. Prophylactic colectomy for gene carriers in hereditary nonpolyposis colorectal cancer. Has the time come? *Cancer.* 1996 Jul 15;78(2):199-201
- Sadahiro** S, Suzuki T, Ishikawa K, Yasuda S, Tajima T, Makuuchi H, Murayama C, Ohizumi Y. Intraoperative radiation therapy for curatively resected rectal cancer. *Dis Colon Rectum.* 2001 Nov;44(11):1689-95
- Schirrmacher** V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. *Int J Oncol.* 2001 May;18(5):945-52
- Schmiegel** W et al, Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung-Vorsorge bei Risikogruppen- Endoskopische Diagnostik von Polypen und Karzinomen, Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften (AWMF), Zeitschrift für Gastroenterologie, 2000, 1:49-75
- Schwartzberg** LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. *Crit Rev Oncol Hematol.* 2001 Oct;40(1):17-24. Review
- Schlag** P.M. Pathomorphologie und Chirurgie-Standards beim kolorektalen Karzinom, Der Onkologe, 1998, Vol 4, Issue 13, S23-S27,
- Schlag** PM, Benhidjep T, Kilpert B, Surgical and multimodality Treatment of colorectal liver-metastases, Onkologie, 1999, 22, 92-97

**Sewing** K-F (Hrsg.), Zum Ersatz von Tierversuchen, Schlütersche Verlagsanstalt und Druckerei GmbH, 1994

**Shand** N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther. 1999 Sep 20;10(14):2325-35

**Singh** S, Cunningham C, Buchanan A, Jolly DJ, Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol Ther. 2001 Aug;4(2):157-60

**Song** YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer *in-vivo* by intravenous administration. Hum Gene Ther. 1997 Sep 1;8(13):1585-94

**Statistisches Jahrbuch 2001**, Hrsg. Statistisches Bundesamt, Metzler Poeschel, Stuttgart, 442 ff.

**Statistisches Jahrbuch1999**, Hrsg. Statistisches Bundesamt, Metzler Poeschel, Stuttgart, 440 ff.

**Sterman** DH, Molnar-Kimber K, Iyengar T, Chang M, Lanuti M, Amin KM, Pierce BK, Kang E, Treat J, Recio A, Litzky L, Wilson JM, Kaiser LR, Albelda SM. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 2000 Dec;7(12):1511-8

**Su** H, Lu R, Ding R, Kan YW. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase / interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol Ther. 2000 Jun;1(6):509-15

**Sung** MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial, Molecular Therapy, 2001 Sep, 4(3), 182-91

**Taguchi** T, Ogawa N, Bunke B, Nilsson B, and DSM Study Group, The use of degradable starch microspheres (Spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumours- results of a phase III clinical trial, Regional Cancer Treatment, 1992, 4:161-165

**Teh BS**, Aguilar-Cordova E, Kernen K, Chou CC, Shalev M, Vlachaki MT, Miles B, Kadmon

D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB. Phase I / II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. *Int J Radiat Oncol Biol Phys.* 2001 Nov 1;51(3):605-13

**Thomas C**, Nijenhuis AM, Timens W, Kuppen PJ, Daemen T, Scherphof GL. Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. *Invasion Metastasis.* 1993;13(2):102-12

**Thurston G**, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. *J Clin Invest.* 1998 Apr 1;101(7):1401-13

**Tjuvajev JG**, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghigian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. *Cancer Res.* 1998 Oct 1;58(19):4333-41

**Tong XW**, Engehausen DG, Kaufman RH, Agoulnik I, Contant C, Freund CT, Oehler MK, Kim TE, Hasenburg A, Woo SL, Kieback DG. Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy. *Anticancer Res.* 1998 Mar-Apr;18(2A):713-8

**Tong X**, Engehausen DG, Freund CTF, Agoulnik I, Oehler MK, Kim T-E, Hasenburg A, Guo Z, Contant CF, Woo SLC, Kieback DG, Comparisation of Long-term Survival of Cytomegalovirus Promotor versus Rous Sarcoma Virus Promotor-Driven Thymidine Kinase gene Therapy in nude Mice Bearing Human ovarian Cancer, Hybridoma; 1999, Vol 18, No. 1, 93-97

**Tono T**, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. *Cancer.* 2000 Apr 1;88(7):1549-56

**Torchilin VP**, Khaw BA, Smirnov VN, Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. *Biochem Biophys Res Commun.* 1979 Aug 28;89(4):1114-9

**Towler B**, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. *BMJ.* 1998 Aug 29;317(7158):559-65

- Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG.** Phase I study of adenoviral delivery of the HSV-*tk* gene and ganciclovir administration in patients with current malignant brain tumors. *Mol Ther.* 2000 Feb;1(2):195-203
- Tumorregister München** <Http://www.med.uni-muenchen.de/trm>
- UICC International Union against Cancer, TNM Klassifikation maligner Tumoren,** Springer-Verlag, 1992, Hrsg. Hermanek, Paul
- van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, van der Eb AJ, Rinkes IH, van de Velde CJ, Hoeben RC.** Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. *Gene Ther.* 1998 Apr;5(4):451-8
- Vahrmeijer AL, van Dierendonck JH, van de Velde CJ.** Treatment of colorectal cancer metastases confined to the liver. *Eur J Cancer.* 1995 Jul-Aug;31A(7-8):1238-42. Review
- Vauthey JN, Marsh Rde W, Cendan JC, Chu NM, Copeland EM.** Arterial therapy of hepatic colorectal metastases. *Br J Surg.* 1996 Apr;83(4):447-55. Review
- Verma IM, Somia N.** Gene therapy -- promises, problems and prospects. *Nature.* 1997 Sep 18;389(6648):239-42
- Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM.** The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. *Ann Surg.* 1984 May;199(5):502-8.
- Wigmore SJ, Madhavan K, Currie EJ, Bartolo DC, Garden OJ.** Does the subspecialty of the surgeon performing primary colonic resection influence the outcome of patients with hepatic metastases referred for resection? *Ann Surg.* 1999 Dec;230(6):759-65; discussion 765-6
- Wildner O, Blaese RM, Morris JC.** Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. *Cancer Res.* 1999 Jan 15;59(2):410-3
- Willeke F, Von Knebel Doeberitz M, Ridder R, Gentherapie von Tumoren- Klinischer Status praesens, Onkologie 1, IV-22,** Hrsg Zeller, zur Hausen, ecomed-Verlag, 6. Erg.Lfg.12/1998
- Willett WC.** Diet and cancer: one view at the start of the millennium. *Cancer Epidemiol Biomarkers Prev.* 2001 Jan;10(1):3-8
- Wilson KM, Stambrook PJ, Bi WL, Pavelic ZP, Pavelic L, Gluckman JL.** HSV-*tk* gene

therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):746-9

**Winkelbauer FW**, Niederle B, Lammer J, Arterielle Embolisationstherapie von Lebermetastasen, Onkologie 2, VI-3, Hrsg Zeller, zur Hausen, ecomed-Verlag, 3. Erg.Lfg.5/1997

**Zetter BR**. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407-24. Review

**Zufferey R**, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery *in-vivo*. Nat Biotechnol. 1997 Sep;15(9):871-5